scispace - formally typeset
Open AccessJournal ArticleDOI

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma

Mark A. Dickson, +13 more
- 01 Jun 2013 - 
- Vol. 31, Iss: 16, pp 2024-2028
TLDR
Treatment with theCDK4 inhibitor PD0332991 was associated with a favorable progression-free rate in patients with CDK4-amplified and RB-expressing WDLS/DDLS who had progressive disease despite systemic therapy.
Abstract: 
Purpose CDK4 is amplified in 90% of well-differentiated (WDLS) and dedifferentiated liposarcomas (DDLS). The selective cyclin-dependent kinase 4 (CDK4)/CDK6 inhibitor PD0332991 inhibits growth and induces senescence in cell lines and xenografts. In a phase I trial of PD0332991, several patients with WDLS or DDLS experienced prolonged stable disease. We performed an open-label phase II study to determine the safety and efficacy of PD0332991 in patients with advanced WDLS/DDLS.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Prospects and Pitfalls of Personalizing Therapies for Sarcomas: From Children, Adolescents, and Young Adults to the Elderly

Vivek Subbiah
- 17 Jul 2014 - 
TL;DR: Challenges remain in implementing the science of precision medicine in the clinic, including providing comprehensive multidisciplinary care and overcoming regulatory and economic hurdles, which must be facilitated within the collaborative framework of academia, industry, federal regulators, and third-party payers.
Journal ArticleDOI

Genetic profiling of primary and secondary tumors from patients with lung adenocarcinoma and bone metastases reveals targeted therapy options.

Long Huang, +11 more
- 17 Sep 2020 - 
TL;DR: Treatment regimens based on comprehensive genetic assessment of newly diagnosed lung adenocarcinoma patients should target both the PT and secondary BMs, including rogue clones with potential to form new BMs.
Journal ArticleDOI

The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy.

Santiago Rello-Varona, +9 more
- 07 Apr 2015 - 
TL;DR: The main objective is to put into context the most recent sarcoma cell death findings in the more general landscape of different cell death modalities.
Journal ArticleDOI

Clinical Trials in Precision Oncology

Susan M. Mockus, +4 more
- 01 Mar 2016 - 
TL;DR: Systematic implementation of reporting standards is needed to insure consistency and specificity of biomarker data, which will in turn enable better comparison and assessment of clinical trial outcomes across multiple studies.
Journal ArticleDOI

Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial

- 01 Aug 2022 - 
TL;DR: In this paper , the authors evaluated the clinical benefit of selinexor in patients with previously treated DD-LPS whose sarcoma progressed on approved agents, and found that the absence of CALB1 expression was associated with longer progression-free survival (PFS) compared with placebo (median 6.9 v 2.2 months; HR, 0.19; P = .001).
References
More filters
Journal ArticleDOI

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

Elizabeth Eisenhauer, +15 more
- 01 Jan 2009 - 
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Book

Statistical methods for rates and proportions

Joseph L. Fleiss
TL;DR: In this paper, the basic theory of Maximum Likelihood Estimation (MLE) is used to detect a difference between two different proportions of a given proportion in a single proportion.
Journal ArticleDOI

Statistical Methods for Rates and Proportions.

B. S. Everitt, +1 more
- 01 Sep 1973 - 
Journal Article

[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].

Hirokazu Watanabe, +9 more
- 01 Dec 2009 - 
TL;DR: This paper is an overview of the new response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1), with a focus on updated contents.
Journal Article

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

David W. Fry, +10 more
- 01 Nov 2004 - 
TL;DR: Results indicate that inhibition of Cdk4/6 alone is sufficient to cause tumor regression and a net reduction in tumor burden in some tumors.
Related Papers (5)

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

David W. Fry, +10 more
- 01 Nov 2004 - 

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Richard S. Finn, +11 more
- 29 Oct 2009 - 

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

Winette T. A. van der Graaf, +22 more
- 19 May 2012 - 

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Richard S. Finn, +17 more
- 01 Jan 2015 - 

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer―Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

Stefan Sleijfer, +12 more
- 01 Jul 2009 -